{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:28:27Z","timestamp":1761236907997},"reference-count":26,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that is unlikely to be cured by treatment with conventional high-dose therapy and autologous stem cell transplantation. We tested the safety and efficacy of using a CD20-specific monoclonal antibody conjugated with 131I to deliver high-dose radiation selectively to all lymphoma sites. Patients with relapsed or refractory mantle cell lymphoma received infusions of 131I-labeled CD20-specific monoclonal antibody (Tositumomab). The antibody dose was 1.7 mg\/kg body weight, and the amount of 131I was calibrated to deliver 20 to 25 Gy to vital normal organs. This treatment was followed 10 days later by administration of high-dose etoposide (30-60 mg\/kg), cyclophosphamide (60-100 mg\/kg), and infusion of cryopreserved autologous stem cells. The 16 patients in this study had received a median of 3 prior treatments, and 7 had chemotherapy-resistant disease. The median dose of 131I was 510 mCi (18.87 GBq). There were no therapy-related deaths. Among the 11 patients with conventionally measurable disease at the time of treatment, the respective complete and overall response rates were 91% and 100%. Fifteen patients remain alive, and 12 have had no progression of lymphoma at 6 to 57 months from transplantation and 16 to 97 months from diagnosis. Overall survival at 3 years from transplantation is estimated at 93%, and progression-free survival is estimated at 61%. High-dose treatment with 131I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma.<\/jats:p>","DOI":"10.1182\/blood.v99.9.3158","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:33:52Z","timestamp":1034361232000},"page":"3158-3162","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":171,"title":["High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma"],"prefix":"10.1182","volume":"99","author":[{"given":"Ajay K.","family":"Gopal","sequence":"first","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Rajendran","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Petersdorf","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet F.","family":"Eary","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon A.","family":"Bush","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence D.","family":"Durack","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Martin","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana C.","family":"Matthews","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irwin D.","family":"Bernstein","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"From the Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, Division of Medical Oncology, Department of Radiology, Division of Nuclear Medicine, Department of Pathology, Department of Biostatistics, and Department of Pediatrics, University of Washington, Seattle, WA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021221301516500_B1","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B2","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: a population-based clinical study.","volume":"14","author":"Velders","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B3","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood."},{"key":"2020021221301516500_B5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/oxfordjournals.annonc.a059156","article-title":"The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma.","volume":"6","author":"Stewart","year":"1995","journal-title":"Ann Oncol."},{"key":"2020021221301516500_B7","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1083-8791(00)70030-9","article-title":"Autologous hematopoietic stem cell transplantation for mantle cell lymphoma.","volume":"6","author":"Vose","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"key":"2020021221301516500_B8","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B9","first-page":"1975","article-title":"Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma.","volume":"10","author":"Haas","year":"1996","journal-title":"Leukemia."},{"key":"2020021221301516500_B10","first-page":"17a","article-title":"High dose therapy with allogeneic or autologous stem cell transplantation for relapsed mantle cell lymphoma: the Seattle experience.","volume":"17","author":"Sohn","year":"1998","journal-title":"Proc Am Soc Clin Oncol."},{"key":"2020021221301516500_B11","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0360-3016(89)90064-3","article-title":"The patterns of failure in patients with pathological stage I and II diffuse histiocytic lymphoma treated with radiation therapy alone.","volume":"17","author":"Hallahan","year":"1989","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2020021221301516500_B12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7326\/0003-4819-104-6-747","article-title":"Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy.","volume":"104","author":"Kaminski","year":"1986","journal-title":"Ann Intern Med."},{"key":"2020021221301516500_B13","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University.","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B14","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.","volume":"329","author":"Press","year":"1993","journal-title":"N Engl J Med."},{"key":"2020021221301516500_B15","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(95)92225-3","article-title":"Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.","volume":"346","author":"Press","year":"1995","journal-title":"Lancet."},{"key":"2020021221301516500_B16","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.","volume":"96","author":"Press","year":"2000","journal-title":"Blood."},{"key":"2020021221301516500_B17","first-page":"1257","article-title":"Imaging and treatment of B-cell lymphoma.","volume":"31","author":"Eary","year":"1990","journal-title":"J Nucl Med."},{"key":"2020021221301516500_B18","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation.","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1702833","article-title":"Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.","volume":"27","author":"Gopal","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"2020021221301516500_B20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.1992.10.6.936","article-title":"Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.","volume":"10","author":"Gulati","year":"1992","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B21","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood.V94.10.3325.422k13_3325_3333","article-title":"Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.","volume":"94","author":"Freedman","year":"1999","journal-title":"Blood."},{"key":"2020021221301516500_B22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","article-title":"International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury.","volume":"17","author":"Shipp","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1520-6823(1999)7:3<186::AID-ROI8>3.0.CO;2-2","article-title":"Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin's lymphoma.","volume":"7","author":"Aref","year":"1999","journal-title":"Radiat Oncol Investig."},{"key":"2020021221301516500_B24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0167-8140(85)80086-4","article-title":"Role of radiation therapy in localized non-Hodgkin's lymphoma.","volume":"4","author":"Sutcliffe","year":"1985","journal-title":"Radiother Oncol."},{"key":"2020021221301516500_B25","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1200\/JCO.1998.16.10.3270","article-title":"Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.","volume":"16","author":"Liu","year":"1998","journal-title":"J Clin Oncol."},{"key":"2020021221301516500_B26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias.","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J Clin Pathol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3158\/1683271\/h80902003158.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/99\/9\/3158\/1683271\/h80902003158.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:31:44Z","timestamp":1581561104000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/99\/9\/3158\/54155\/Highdose-chemoradioimmunotherapy-with-autologous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v99.9.3158","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5,1]]}}}